Skip to main content
logo
Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
58.27
+0.30 (0.52%)
Aug 11, 2026, 12:35 PM EDT - Market open

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15
Cystic Fibrosis Franchise Revenue
855.89M828.18M826.21M
Evrysdi Revenue
221.14M206.97M224.43M
Trelegy Revenue
160.44M154.10M146.92M
Tremfya Revenue
191.36M152.94M147.14M
Voranigo Revenue
172.98M154.42M46.15M
Tysabri Revenue
111.38M116.88M124.82M
Other Products Revenue
691.07M647.67M633.76M
Total Income from Financial Royalty Assets
2.40B2.26B2.15B
Other Royalty Income and Revenue
131.74M117.04M114.15M
Revenue (Other)
-172.98M-154.42M-46.15M
Revenue (Total)
2.54B2.38B2.26B

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15
Portfolio Receipts
3.39B3.25B2.80B